• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    6/6/25 4:05:24 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLS alert in real time by email
    false 0001390478 0001390478 2025-06-03 2025-06-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): June 3, 2025

     

    SELLAS Life Sciences Group, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33958   20-8099512
    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)
             
        7 Times Square, Suite 2503
    New York, NY 10036
       
        (Address of Principal Executive
    Offices) (Zip Code)
       
             
    Registrant’s telephone number, including area code: (646) 200-5278

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading
    symbol(s)
    Name of each exchange on which
    registered
    Common Stock, $0.0001 par value per share SLS The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

    Item 4.01 Changes in Registrant’s Certifying Accountant

     

    On June 3, 2025, SELLAS Life Sciences Group, Inc.’s (the “Company”) independent registered public accounting firm, Moss Adams LLP (“Moss Adams”), merged with Baker Tilly US, LLP. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the merger, Moss Adams has resigned as the auditors of the Company and on June 3, 2025, the Audit Committee of the Company’s Board of Directors accepted the resignation of Moss Adams and approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm.

     

    The audit report of Moss Adams on the Company’s consolidated financial statements as of and for the years ended December 31, 2024 and 2023, did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. Moss Adams’ audit report on the consolidated financial statements contained an explanatory paragraph regarding a going concern uncertainty.

     

    During the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through the date of this Current Report on Form 8-K, there were no (a) disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K with Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Moss Adams’ satisfaction, would have caused it to make reference to the subject matter of the disagreement in connection with its reports on the Company’s financial statements, and (b) reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K.

     

    On June 3, 2025, the Company engaged Baker Tilly as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.

     

    During the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through the date of this Current Report on Form 8-K, neither the Company, nor anyone on its behalf, consulted with Baker Tilly regarding: (i) either the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; (ii) any matter that was either the subject of a “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to that item, or (iii) any reportable event within the meaning of Item 304(a)(1)(v) of Regulation S-K.

     

    The Company provided Moss Adams with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (the “Commission”) and requested that Moss Adams furnish the Company with a letter addressed to the Commission stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of Moss Adams’ letter to the Commission, dated June 6, 2025, is filed as Exhibit 16.1 to this Form 8-K and is incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    16.1   Letter from Moss Adams Dated June 6, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      SELLAS Life Sciences Group, Inc.
         
    Date: June 6, 2025 By: /s/ John T. Burns
        Name: John T. Burns
        Title: Senior Vice President, Chief Financial Officer

     

     

     

    Get the next $SLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLS

    DatePrice TargetRatingAnalyst
    7/21/2021$18.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

      Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

      6/24/25 12:52:00 PM ET
      $AUTL
      $CATX
      $INDP
      $ONCY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

      NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000® and Russell 2000® Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies and serves as a broad benchmark for the U.S. equity market. The Russell 2000® Index, a subset of the Russell 3000®, measures the performance

      6/24/25 8:00:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

      NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisory Board (SAB). The new members – Philip C. Amrein, MD, and Alex Kentsis, MD, PhD bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the company's strategic guidance as it advances its therapeutic pipeline. "We are honored to welcome Drs. Amrein and Kentsis to our Scientific Advisor

      6/5/25 8:45:00 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on SELLAS Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00

      7/21/21 11:28:03 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital initiated coverage on Solaris Resources with a new price target

      RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00

      6/21/21 6:52:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/13/25 8:00:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/2/25 4:42:07 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      5/22/25 4:05:17 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/13/25 8:00:33 AM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      6/2/25 4:42:07 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

      4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

      5/22/25 4:05:17 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLS
    SEC Filings

    See more
    • SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      6/18/25 5:11:02 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.

      DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      6/10/25 4:05:23 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

      6/6/25 4:05:24 PM ET
      $SLS
      Biotechnology: Pharmaceutical Preparations
      Health Care